WuXi AppTec

WuXi AppTec provides a broad portfolio of research and development and manufacturing services that enable companies in the pharmaceutical, biotech, and medical device industries worldwide to advance discoveries and deliver treatments to patients. The company is engaged in the discovery, development, and production of small molecule drugs, cell therapies, and gene therapies; they provide laboratory services for synthetic chemistry, medicinal chemistry, analytical chemistry, biology, drug metabolism and pharmacokinetics, metabolism, excretion, toxicology, and bioanalytical services; and they provide testing services for medical devices.

The segments of WuXi AppTec include China-based laboratory services, United States-based laboratory services, clinical and contract research services, and contract manufacturing and contract development services (CMO/CDMO services). WuXi AppTec also offers an open-access platform to help enable collaborators to develop pharmaceuticals and therapeutics to improve the health of patients. WuXi AppTec quotes there to be more than 3,900 collaborators from over thirty countries, .

In 2007, WuXi AppTec began trading on the New York Stock Exchange and traded under the ticker symbol WX.

In 2018, WuXi AppTec was listed on the Hong Kong exchange, where it raised $1 billion in its Hong Kong initial public offering (IPO) and valued the firm at $10.2 billion. The debut of WuXi AppTec was considered to be subdued and flat, as the share price opened at HK$67 and closed the day HK$68. In the same year, the company announced the listing of shares on the Shanghai Stock Exchange.

WuXi AppTec's platform offers customers access to a range of capabilities and services to help those customers develop new medicines and support the research and development of those medicines. The integrated, open-access platform works to increase the capabilities of anyone to research and develop and expedite the development and delivery of new medicines.

The platform includes WuXi Chemistry, which provides CRDMO services for new drug development, including the stages from discovery to commercialization. It can work to meet any material requirement at any scale and cover categories such as synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates.

For WuXi Biology, the platform works to provide a spectrum of biology solutions and services for the support of projects, whether they are stand-alone or integrated projects, and from target discovery to candidate selection. The platform also offers testing, through WuXi Testing, which provides drug and medical device testing services from preclinical to clinical trials.

The platform also offers contract testing development and manufacturing, through WuXi Advanced Therapies, which offers an integrated end-to-end solution to accelerate time to market for cell and gene therapies. And the platform provides drug discovery services to pharmaceutical and biotechnology companies operating in China through WuXi DDSU.

The services offered by WuXi NextApp include research and development and manufacturing services, CRDMO (contract research, development, and manufacturing organization) services, biology discovery, preclinical testing, clinical research services, and cell and gene therapy CTDMO (contract testing, development, and manufacturing organization) services.

Offered through the Research Service Division of WuXi AppTec, the biology discovery service includes the provision of hits finding, discovery biology, oncology and immunology, and discovery services for customers in the therapeutic areas of cardiovascular diseases, metabolic diseases, fibrosis lung, liver, and kidney, central nervous system and pain, respiratory diseases, infectious disease, and autoimmune and inflammatory diseases.

Through its small molecule services, the company works to deliver synthetic and medicinal chemistry solutions to global pharmaceutical and biotechnology customers for the identification, creation, and support of the discovery of preclinical candidates through a discovery chemistry platform. The capabilities of this service include an integrated CMC platform for both API and drug products and eight development and manufacturing sites. The service has previously supported 23 new drugs approved between 2017 to 2020 and has supported at least 1,113 preclinical and phase I trials, 220 phase II trials, 48 phase III trials, and 32 commercial products.

WuXi AppTec's Laboratory Testing Division is a testing platform for drug and medical device development. The integrated drug testing platform includes preclinical drug development and clinical drug development services, and works to support clients from research through to market. For medical device testing, the platform offers chemistry, microbiology, biocompatibility, large animal research, risk assessment, and registration services.

WuXi Clinical services include contract research services, such as clinical development from Phase I to Phase IV clinical development services and bioequivalence for products including pharmaceuticals, biologics, and medical devices. The expertise of the services span major therapeutic areas and offer an experienced team capable of combining creativity, responsiveness, and customer centric-focus to work on a variety of products.

The WuXi AppTec services and solutions include those for oligonucleotide services, including a shop to create monomer-oligo-conjugates. Through this, the company offers monomer synthesis, oligonucleotide synthesis, and oligo-conjugate synthesis. The platform covers ASO, siRNA, Aptamer, microRNA, PMO, and oligonucleotide conjugates including GalNAc, PMO-based conjugates, and oligo-toxin and oligo-antibodies. The platform also offers a full suite of analytical testing, conjugation chemistry, solid phase and liquid phase synthesis, linker and ligand synthesis, GalNAc synthesis, and custom phosphoramidite synthesis.

WuXi STA is a subsidiary of WuXi AppTec and is a platform for pharmaceutical development and manufacturing capability and technology for the life sciences industry. WuXi STA is also a contract development and manufacturing organization and offers partners solutions for chemical, manufacturing, and control services for preclinical to commercial products.

For cell and gene therapy services, WuXi AppTec offers contract development and manufacturing services to accelerate and transform the development, manufacturing, and commercialization of cell, gene, and related biopharmaceutical products. The testing services provided include analytical development, cell line characterization, lot release, materials characterization, and viral clearance validation. The products testing includes advanced therapies, protein therapies, and vaccines.

In order for WuXi AppTec to develop a comprehensive capability and technology platform in the global pharmaceutical and healthcare industry, the company has a range of division and subsidiaries to provide the platform to provide and develop those capabilities. This includes a Research Service Division, Laboratory Testing Division, STA Pharmaceutical, Advanced Therapies Unit, WuXi Clinical, WuXi Jinshi Pharmaceutical Technology, and LabNetwork.

The Research Service Division works to deliver preclinical discoveries through discovery biology, hits finding, and discovery for oncology and immunology. The therapeutic areas of research include cardiovascular disease; metabolic disease; fibrosis lung, liver, kidney conditions; central nervous system issues and pain; respiratory ailments, including asthma and COPD; infectious diseases; oncology and immunology; and autoimmune and inflammatory conditions.

WuXi AppTec's Laboratory Testing Division provides an integrated testing platform supporting customers across the spectrum of their development efforts to deliver medicines to patients. This is to help support customers through the drug development journey from drug discovery, to preclinical and clinical trials, and to the challenges of developing a drug. These services include bioanalytical services, to help support drug discovery and move a program through preclinical to clinical development; DMPK services, which offer in vitro and in vivo solutions from high-throughput screening for drug discovery in drug development phases; and safety assessment services, in which toxicologists work or provide comprehensive safety assessments across a range of species and through various routes of administration.

WuXi STA, or STA Pharmaceutical, is a subsidiary of WuXi AppTec which works to provide pharmaceutical development and manufacturing capabilities and platform for the life sciences industry. WuXi STA offers its partners solutions for integrated chemical, manufacturing, and control from preclinical to commercial development. The services provided by WuXi STA include API process development and manufacturing, formulation development and manufacturing, oligonucleotide process development and manufacturing, peptide process development and manufacturing, analytical development and quality control, and global regulatory affairs CMC filing.

WuXi Advanced Therapies is a subsidiary of WuXi AppTec, and works to provide integrated contract testing development and manufacturing organization (CTDMO). This includes cell and gene therapy manufacturing and testing, and advanced and protein therapies and vaccines development, testing, and manufacturing. WuXi Advanced Therapies provides solutions from gene of interest to global commercial launch, which has included viral clearance validation strategies for continuous chromatography; first in human, faster-GMP viral vector platform; designing an extractable and leachable study based on a preferred protocol; and GMP cell bank manufacturing and CLC.

WuXi Clinical is a subsidiary of WuXi AppTec, and works to provide customers with clinical development solutions with dedicated resources in over sixty countries.

WuXi Jinshi Pharmaceutical Technology is a subsidiary of WuXi AppTec that was established in 2009 to conduct clinical research in its expertise areas, including tumor, endocrinology, cardiovascular, respiratory, digestive, neurological, rheumatism, ophthalmology, and infections. The professional services provided by WuXi AppTec include research, research center recommendation and start-up, subject recruitment, patient education and management, data entry, research center closure, quality control verification, and auditing.

WuXi LabNetwork is a subsidiary of WuXi AppTec. LabNetwork is a global e-commerce platform for suppliers and buyers of research products. This includes expertise in research and development, sourcing, quality control, warehousing, and logistics. The company provides web and mobile tools for customers to use, which are capable of using keyword, chemical structure, or list search function to intelligently rank possible compounds and products to get the best results. LabNetwork also features a multi-language, multi-currency, shopping car, quote, checkout, and order tracking capabilities.

In 2015, WuXi AppTec spun out WuXi NextCODE after the company acquired NextCode, a spinout of deCode. This was a genomics platform with the idea to apply the platform to patient care using a massive genomics database and to help researchers interpret patients' DNA and diagnose diseases faster.

WUXI PharmaTech was founded in 2000 and registered in the city of Wuxi, Jiangsu and operated out of Shanghai. Early on, the company offered synthetic chemistry services, before expanding in 2003 to offer manufacturing process development services, and again in 2004 to offer manufacturing services for research and development. From that point, WuXi PharmaTech has continued to expand its offerings, from the expansion to bio-analytical services in 2005, antibody discovery and process development services in 2006 and 2007.

In that same year, the company was listed on the New York Stock Exchange under the ticker symbol WX, and the company set up the Life Science and Chemistry Awards aimed at stimulating innovation and excellence in the life sciences and clinical research.

In 2008, to help the company continue to expand its geographic footprint and its services, WuXi acquired AppTec Laboratory Services, which had locations in Minnesota, Pennsylvania, and Georgia. The company renamed to WuXi AppTec and has retained that name since. Following that, WuXi AppTec opened a toxicology facility in Suzhou, from where it began offering toxicology services. In 2011, WuXi AppTec acquired Medkey, and expanded to clinical development and registration services.

In 2012, a research and development and manufacturing site in the city of Wuxi was developed and opened, which became a central part of WuXi AppTec's strategic network in central and western China. Two years later, WuXi AppTec continued to expand, opening a new facility in Philadelphia to strengthen research and development and production services for therapies and immunotherapies. In the same year, WuXi AppTec's Laboratory Testing Division expanded through the acquisition of XenoBiotic Laboratories, located in Plainsboro, New Jersey, and offering WuXi AppTec a chance to expand and strengthen its bioanalytical and DMPK/ADME services to United States based customers.

In 2015, WuXi AppTec launched medical device testing in China. A year later, the company acquired Crelux, which allowed WuXi AppTec to develop its structure-based drug discovery capabilities in Europe. And in 2017, WuXi AppTec set up an Advanced Therapy Unit in Philadelphia to develop its cell and gene therapy capabilities. The company acquired HD Bioscience from San Diego in the same year to further increase its biology research and development capacity and capability in the United States. In 2017, they also acquired ResearchPoint Global.

In 2018, WuXi AppTec built up the company's Life Science Industry Park in Chengdu. The same year saw the company announce it would be listed on the Shanghai Stock Exchange and listed shares on the Hong Kong Stock Exchange. In 2019, WuXi AppTec acquired Pharmapace for the company's biometrics services for clinical development. And in 2021, WuXi AppTec acquired OXGENE in order to develop and strengthen the company's cell and gene therapy service offerings for its customers.